Before Chris Apfel built a company around hundreds of living microtumors, he made his name with four checkboxes. The simplified Apfel Score, published with collaborators in 1999, gave clinical teams a practical way to estimate the risk of postoperative nausea and vomiting. Its inputs were deliberately ordinary. Its usefulness came from turning a fuzzy judgment into a repeatable one.
More than two decades later, the scale of the problem has changed. The instinct has not. At SageMedic, Apfel is trying to make an oncology decision more observable before it reaches the patient. The Redwood City laboratory receives fresh tumor tissue, prepares hundreds of three-dimensional microtumors, applies a range of therapies, and measures response. The company says it returns findings to physicians in seven to ten days.
The language around the work can become grand very quickly: precision medicine, functional profiling, individualized treatment. Apfel's version is more concrete. Preserve living tissue. Run an experiment. Give the clinician a report while the result can still inform a choice. The laboratory does not replace the oncologist. It adds a new piece of evidence to the room.
A career built around the next decision
Apfel studied medicine and completed doctoral work at Justus Liebig University Giessen in Germany, then trained in anesthesiology, intensive care medicine, and emergency medicine at the University of Würzburg. At the University of California, San Francisco, he practiced, taught, and led clinical research. His publication record grew beyond 100 peer-reviewed papers, including the work that produced the Apfel Score.
The score survives because it is compact enough to travel. It does not demand an elaborate apparatus. Four routinely available factors yield an estimate a clinical team can use. The deeper product lesson is easy to miss: a model becomes consequential when it fits the tempo and constraints of the decision-maker.
“My question was always what improves patient outcomes?”Chris Apfel, reflecting on his clinical research
That sentence is a good map of his career. It explains the move from Germany to UCSF, from academic work to industry, and from the design of trials to the design of a laboratory service. He later worked as an executive director at Cadence Pharmaceuticals, where his work included health-economic research. He also earned an MBA from the Wharton School. The scientist acquired the vocabulary of budgets, commercialization, and organizational design without dropping the original question.
When the abstract becomes physical
SageMedic emerged from a mismatch Apfel saw between the promise of genomic precision and the decision a family actually faces. Genomic tests can reveal mutations and suggest targeted options, but not every tumor presents an actionable mutation, and a molecular match does not guarantee a response. Functional testing approaches the question from the other direction. Instead of inferring behavior only from a molecular profile, it observes what living tumor material does when exposed to therapy in the laboratory.
The idea itself is older than the company. Earlier methods often depended on successfully growing tumor cells, which could take too long or fail. SageMedic's method is designed to create many microtumors without waiting for prolonged growth. A biopsy can be divided into enough testable units to compare drugs and combinations while preserving characteristics of the original tissue.
Timing becomes part of the technology. An exquisite answer delivered after a decision is less useful than a solid answer delivered before it. SageMedic reports results in more than 90 percent of cases within its stated seven-to-ten-day window. Its current site describes the SAGE Oncotest as laboratory information that supports treatment planning, careful language that places judgment with the physician.
“We have a result back for you and the oncologist within seven to 10 days in over 90 percent of cases.”Chris Apfel on the SAGE Oncotest workflow
There is an operational catch hiding inside the science. The specimen must stay fresh. A sample preserved by standard tissue-fixation methods can no longer be used for a live response test. That means coordination has to happen before surgery or biopsy. The lab, patient, physician, and collection site have to act as one temporary supply chain. Precision begins with logistics.
The investor at the lab bench
Apfel is also an impact investor and has chaired the life-science committee for Northern California chapters of Keiretsu Forum. He has reported making more than 20 life-science investments, including Mission Bio, CorInnova, Pathware, and Raydiant Oximetry. This side of his career sharpens the contrast between software mythology and biotechnology reality.
In an investor interview, Apfel used the phrase “gray hair” for meaningful industry experience. His argument was not a complaint about young founders. It was an observation about the shape of the work. A life-science company needs clinical perspective, scientific depth, regulatory patience, reproducible evidence, and people who know how a product will fit into practice. A clever prototype cannot carry all of that alone.
What builders can steal
Design for decision time
Accuracy matters. So do turnaround, workflow, and the moment when evidence enters the room.
What teams can steal
Match experience to risk
In regulated science, domain depth is part of the product, not a decorative credential.
The point lands because Apfel has occupied nearly every chair he describes. He has been a clinician reading evidence, a researcher producing it, an executive commercializing it, an investor assessing the team, and a founder responsible when the pieces do not line up. SageMedic is the accumulation of those roles.
The simplified Apfel Score is published after cross-validation between two centers.
Chris and Brigitte Apfel co-found SageMedic.
Apfel presents the company's functional diagnostic approach at PMWC Silicon Valley.
SageMedic reports CLIA laboratory accreditation through COLA and CMS.
The company presents live sarcoma tissue research at the ASCO Annual Meeting.
A second act that rhymes
The neat version of Apfel's story is that an anesthesia researcher became an oncology founder. The more revealing version is that he kept working on the same intellectual problem. How do you compress uncertainty into evidence that can improve the next decision?
The Apfel Score answered with four factors. SageMedic answers with hundreds of microtumors. One is a paper-and-pencil prediction model; the other requires fresh tissue, laboratory infrastructure, a clinical network, and a company. The second act is vastly more complex, but it rhymes with the first.
Now the work is moving from technical proof toward adoption. SageMedic formed scientific, medical, and business advisory boards in 2024. In 2025, it presented data from live sarcoma tissue at the American Society of Clinical Oncology annual meeting. Apfel also published a public article making the case for functional precision oncology and presented the SAGE Oncotest at InnovatorMD World Congress.
He and his collaborators have added an access project as well. The Partnership for Advanced Cancer Treatment, built with Partnerships for Change, is intended to help fund tests for people who cannot afford them and to support the evidence base for wider use. It makes explicit an aspiration that runs underneath the company: a laboratory technique matters at scale only if patients and clinicians can reach it.
Apfel's career offers no clean shortcut. It offers something more useful: a picture of compounding expertise. Medical training supplied the context. Clinical research supplied the method. UCSF supplied the environment. Industry supplied operating discipline. Wharton supplied a business lens. Angel investing supplied pattern recognition. SageMedic is where those experiences meet.
The useful restraint in the pitch
Listen closely to how Apfel describes the company and a notable restraint appears. He talks about supporting decisions, identifying resistance, and providing options that are more likely to be effective. These are calibrated claims, suited to a laboratory service that enters a larger clinical process. The wording reflects a scientist's respect for what one experiment can and cannot settle, and an operator's understanding that trust is built with boundaries.
That restraint also separates a practical tool from a technology demonstration. A colorful plate of microtumors is visually persuasive, but the intended product is a decision aid with a chain of custody, a turnaround promise, a report format, and a place in an existing workflow. Each unglamorous detail carries part of the scientific idea. Miss the shipping window, preserve the sample incorrectly, or deliver an opaque result, and the elegance at the bench loses its leverage.
Apfel's public comments reveal a similar temperament as an investor. He emphasizes reproducibility, independent judgment, and teams that combine clinical and scientific experience. He does not present regulation as an obstacle that clever founders can talk around. It is part of the terrain. In his framing, the upside in life science exists because approval and adoption are hard, not because those difficulties can be ignored.
This makes his aspiration unusually legible. SageMedic is not trying to make every medical decision automatic. It is trying to make one consequential decision better informed. The company must prove that the signal observed in its laboratory is reliable, useful to physicians, and available to more people. Advisory boards, conference data, the access partnership, and the CLIA laboratory are different pieces of that same adoption problem.
The four checkboxes and the hundreds of microtumors belong to different eras of his work, yet both make invisible uncertainty visible. That is the through-line, and it is why his current bet feels less like a pivot than a continuation.